Prognostic stratification of HPV-associated oropharyngeal cancer based on CD103

Cetuximab Head and Neck Neoplasms / complications Humans Oropharyngeal Neoplasms / pathology Papillomaviridae Papillomavirus Infections / complications Prognosis Randomized Controlled Trials as Topic
CD103 cetuximab cisplatin head and neck cancer human papillomavirus oropharyngeal cancer

Journal

Annals of oncology : official journal of the European Society for Medical Oncology
ISSN: 1569-8041
Titre abrégé: Ann Oncol
Pays: England
ID NLM: 9007735

Informations de publication

Date de publication:
08 2022
Historique:
received: 09 02 2022
revised: 14 04 2022
accepted: 18 04 2022
pubmed: 8 5 2022
medline: 4 8 2022
entrez: 7 5 2022
Statut: ppublish

Résumé

High CD103 We pooled data from the TROG 12.01 and De-ESCALaTE randomized trials that compared CETUX/70GyRT with CIS/70GyRT in low-risk HPV-associated OPSCC: American Joint Committee on Cancer 7 stage III (excluding T1-2N1) or stage IV (excluding N2b-c if smoking history >10 pack-years and/or distant metastases), including all patients with available tumor samples. The primary endpoint was failure-free survival (FFS) in patients receiving CETUX/RT comparing CD103 Tumor samples were available in 159/182 patients on TROG 12.01 and 145/334 on De-ESCALaTE. CD103 CD103

Sections du résumé

BACKGROUND
High CD103
PATIENTS AND METHODS
We pooled data from the TROG 12.01 and De-ESCALaTE randomized trials that compared CETUX/70GyRT with CIS/70GyRT in low-risk HPV-associated OPSCC: American Joint Committee on Cancer 7 stage III (excluding T1-2N1) or stage IV (excluding N2b-c if smoking history >10 pack-years and/or distant metastases), including all patients with available tumor samples. The primary endpoint was failure-free survival (FFS) in patients receiving CETUX/RT comparing CD103
RESULTS
Tumor samples were available in 159/182 patients on TROG 12.01 and 145/334 on De-ESCALaTE. CD103
CONCLUSIONS
CD103

Identifiants

DOI: 10.1016/j.annonc.2022.04.074 PMID: 35525376
pubmed: 35525376
pii: S0923-7534(22)00764-5
doi: 10.1016/j.annonc.2022.04.074
pii:
doi:

Substances chimiques

Cetuximab PQX0D8J21J

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

804-813

Subventions

Organisme : Cancer Research UK
ID : 12834
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N005872/1
Pays : United Kingdom

Informations de copyright

Copyright © 2022 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure DR—grants from Merck Sharp & Dohme, grants from Merck KGaA, grants from Bristol-Myers Squibb, grants from GSK, grants from Roche, grants from Regeneron, grants from Kura Oncology, grants from ALX Oncology, trial steering committees and/or advisory boards (all uncompensated)—MSD, GSK, Regeneron, Sanofi; HM—grants from Astra Zeneca, grants from GSK Biologicals, grants from GSK, trial steering committees and/or advisory boards—Astra Zeneca, Merck Sharp and Dohme, Merck KGaA and GSK; JC—grants from Merck KGgA, advisory board Merck KGgA Sandro Porceddu—advisory boards Merck Sharp & Dohme, Merck KGgA, Steering Committee Regeneron; CW—advisory board Merck KGgA; BJS—research grant from Sanofi-Regeneron; advisory boards or consultancies—Bristol-Myers Squibb, Merck Sharp & Dohme, AstraZeneca, Pfizer, Roche/Genentech, Amgen, Lilly, Sanofi, Glaxo-Smith Kline, Takeda and BeiGene; has been compensated for royalties UpToDate. All other authors have declared no conflicts of interest.

Auteurs

D Rischin (D)

Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia. Electronic address: danny.rischin@petermac.org.

H Mehanna (H)

Institute of Head and Neck Studies and Education (InHANSE), University of Birmingham, Birmingham, UK.

R J Young (RJ)

Research Division, Peter MacCallum Cancer Centre, Melbourne, Australia.

M Bressel (M)

Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Australia.

J Dunn (J)

Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.

J Corry (J)

Genesiscare St Vincent's Hospital, Melbourne, Australia; Department of Medicine, University of Melbourne, Melbourne, Australia.

P Soni (P)

Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia.

T Fulton-Lieuw (T)

Institute of Head and Neck Studies and Education (InHANSE), University of Birmingham, Birmingham, UK.

G Iqbal (G)

Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.

L Kenny (L)

Department of Radiation Oncology, Royal Brisbane & Women's Hospital, Brisbane, Australia; Faculty of Medicine, University of Queensland, Brisbane, Australia.

S Porceddu (S)

Faculty of Medicine, University of Queensland, Brisbane, Australia; Department of Radiation Oncology, Princess Alexandra Hospital, Brisbane, Australia.

C Wratten (C)

Department of Radiation Oncology, Calvary Mater Hospital and University of Newcastle, Newcastle, Australia.

M Robinson (M)

Cellular Pathology, Newcastle upon Tyne Hospitals, Newcastle, UK.

B J Solomon (BJ)

Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Research Division, Peter MacCallum Cancer Centre, Melbourne, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Cétuximab › Prognostic stratification of HPV-associated...
questionsmedicales.fr › Tumeurs › Tumeurs par siège › Tumeurs de la tête et du cou › Prognostic stratification of HPV-associated...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Prognostic stratification of HPV-associated...
questionsmedicales.fr › Maladies oto-rhino-laryngologiques › Maladies du pharynx › Tumeurs du pharynx › Tumeurs de l'oropharynx › Prognostic stratification of HPV-associated...
questionsmedicales.fr › Virus › Virus oncogènes › Virus tumoraux à ADN › Papillomaviridae › Prognostic stratification of HPV-associated...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladies transmissibles › Maladies sexuellement transmissibles › Maladies sexuellement transmissibles virales › Infections à papillomavirus › Prognostic stratification of HPV-associated...
questionsmedicales.fr › Diagnostic › Pronostic › Prognostic stratification of HPV-associated...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études cliniques comme sujet › Essais cliniques comme sujet › Essais cliniques contrôlés comme sujet › Essais contrôlés randomisés comme sujet › Prognostic stratification of HPV-associated...